Bit Capital Gmb H Ultragenyx Pharmaceutical Inc. Transaction History

Bit Capital Gmb H

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$31.06 - $39.3 $608,776 - $770,280	-19,600 Reduced 90.51%	2,055 $74.7 Million
Q1 2025 May 09, 2025	SELL	$36.21 - $45.78 $297,465 - $376,082	-8,215 Reduced 27.5%	21,655 $784 Million
Q3 2024 Feb 12, 2025	SELL	$40.21 - $59.36 $95,900 - $141,573	-2,385 Reduced 7.39%	29,870 $1.66 Billion
Q2 2024 Feb 12, 2025	SELL	$37.42 - $51.61 $327,237 - $451,329	-8,745 Reduced 21.33%	32,255 $1.33 Billion
Q1 2024 Feb 12, 2025	BUY	$43.02 - $53.69 $1.7 Million - $2.12 Million	39,445 Added 2536.66%	41,000 $1.91 Billion

Q4 2023 Feb 12, 2025	BUY	$31.73 - $49.19 $49,340 - $76,490	1,555 New	1,555 $74.4 Million

348

88.2M

2.19M

1.04M

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.32B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

Stay updated on Bit Capital Gmb H with notifications on news.